Olaparib for the Treatment of Patients With Metastatic Castration-Resistant Prostate Cancer and Alterations in BRCA1 and/or BRCA2 in the PROfound Trial.
Joaquin MateoJohann S de BonoKarim FizaziFred SaadNeal D ShoreShahneen SandhuKim N ChiArchana M AgarwalDavid OlmosAntoine Thiery-VuilleminMustafa ÖzgüroğluNiven MehraNobuaki MatsubaraJae Young JoungCharles PaduaErnesto KorbenfeldJinyu KangHelen MarshallZhongwu LaiAlan BarnicleChristian PoehleinNatalia LukashchukMaha H A HussainPublished in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2023)
In all subgroups assessed, olaparib improved outcomes versus abiraterone or enzalutamide for patients with mCRPC with BRCA alterations whose disease had progressed on previous NHA.